Cancer Tissue Diagnostics Market

Evolution of Cell and Gene Therapies Drives Global Cancer Tissue Diagnostics Market

The Cancer Tissue Diagnostics Market is valued at USD 16.9 Bn in 2026 and is projected to reach USD 23.4 Bn,  growing at a CAGR of 5% by 2033.Unprecedented rise in cancer cases worldwide has placed cancer tissue diagnostics market at pivotal stage in timely diagnosis and treatment of cancer. Technological advancements such as automation and innovative diagnostics therapies use of high-quality biomarkers have helped the medical fraternity in apt treatment of various types of cancers. The ever evolving cell and gene therapies have opened new avenues and innovative approaches in cancer treatment through personalized medicine. The cancer tissue diagnostics market was valued to be US$3.9 Bn in 2021 and is expected to reach approximately US$5.7 Bn by 2027 at a CAGR of 6.8% from 2022 to 2027. Growing awareness, rise in cancer screening programs coupled with improved healthcare expenditure and favorable reimbursement policies are fueling the growth of the market. However, lack of skilled professionals and infrastructure in mid and low income countries will hinder the cancer tissue diagnostics market growth during the forecast.           

Precision Medicine to Drive Cancer Tissue Diagnostics Market

Precision medicine is a new and innovative way to treat cancer which involves tailor made approaches in genetic screening and analysis conducted through tissue diagnostics and help in understanding the genetic makeup and genetic profile of the affected tissue or tumor and then tailor made medicines are prescribed based on the genetic tendency that cause a specific cancer. Various tissue diagnostics methods such as immunohistochemistry, molecular oncology, chromosome analysis and mutational studies of DNA and RNA analysis has helped the pathologists differentiate the type and stages of various cancers. However, high costs of these diagnostics tests and personal data theft are major factors that restrict the market growth.

Automation and Digitalization to Promotes Cancer Tissue Diagnostics Market Growth

Innovations in pre-analytical and analytical staining through adoption of automated staining equipment and digital platforms has revolutionized the tissue diagnostic market. Growing pressures for timely results and lack of skilled professional has instigated the market for digital pathology. Digitalization has helped in providing whole slide images, digital duplication of biopsy tissue through use of high resolution scanners and is made visible on large computer screens. Moreover, high through put pathological scanners provide high quality of images essential for pathologists for detection of malignant changes. High throughput next generation sequencers, high quality of biomarkers and advanced software are expected to propel the market growth. In addition, data storage, archiving and retrieving the pathological images for future references through use of Artificial Intelligence is expected to bring a transformational change in cancer diagnosis during forecast period.

Collaborations and Partnerships to be Strategy for Players

Collaborations between companion diagnostics vendors and cancer tissue diagnostics market players would be a primary driver for market growth and establishment. For instance In February 2022, Genetron Health a leading precision oncology platform company has collaborated with Hutchemed for companion diagnostic test for ORPATHYS (savoltinib) in China for Lung Cancer Assay. In March 2022, Myriad Genetics a major player in genetic testing and precision medicine announced approval of its BRACAnalysis® a companion diagnostic test to identify germline BRCA mutated  HER2 negative, high-risk early-stage breast cancer who may benefit from Lynparza®(olaparib). In March 2022, Roche announced collaboration with Bristol Myers Squibb. Roche will support advancements of two assays. Under first collaboration, Roche Digital Pathology will use of AI to develop new digital pathology algorithms to help pathologists interpret VENTANA PD-L1 (SP142) Assay while BMS will use the algorithms to create biomarker data from clinical trial samples. Whereas, the second collaboration, Roche will use PathAI-developed algorithm for CD8 biomarker analysis into the NAVIFY Digital Pathology workflow software. This AI powered algorithm will be used by BMS to analyze to analyze clinical trial samples that have been stained with Roche's CD8 assay and generate quantitative spatial biomarker data. Thus, this will be the first time Roche would leverage its PathAI collaboration (for AI) and its digital pathology applications to better identify targeted therapy options.

North America to Drive Cancer Tissue Diagnostics Market Growth

Well established healthcare infrastructure, cancer research centers and strong government initiatives such as reimbursements for diagnostic tests makes US the major market in North American region. Ever growing awareness of cancer through cancer funding programs and screening programs has resulted in rise in demand for pathological tests in the country. Europe accounted for the second largest market followed by Asia. Asia is expected to foresee the highest growth owing to rise cancer incidence, huge investments made in healthcare infrastructure especially in China and India is expected to boost the market in Asian region.

Cancer Tissue Diagnostics Market: Competitive Landscape

The major players in the global cancer tissue diagnostics market are 

• Roche Diagnostics
• Abbott Laboratories
• Thermo Fisher Scientific
• Agilent Technologies
• Siemens Healthineers
• Danaher Corporation
• Sysmex Corporation
• BD (Becton, Dickinson and Company)
• Hologic, Inc.
• Bio Rad Laboratories
• Qiagen N.V.
• Merck KGaA (MilliporeSigma)
• Hoffmann La Roche Ltd.
• Sakura Finetek Japan Co., Ltd.
• Illumina, Inc.

Global Cancer Tissue Diagnostics Market is Segmented as Follows:

By Product

• Consumables
• Antibodies
• Kits
• Reagents
• Probes
• Instruments
• Slide Staining System
• Scanner
• Tissue Processing system
• Other instruments

By Technology

• Immunohistochemistry (IHC)
• In Situ Hybridization (ISH)
• Digital Pathology and Workflow Management
• Special Staining

By Disease

• Breast Cancer
• Gastric Cancer
• Lymphoma
• Prostate Cancer
• Non-Small Cell Lung Cancer (NSCLC)
• Other Diseases

By End User

• Hospitals
• Research Laboratories
• Pharmaceutical Companies
• Contract Research Organizations
• Other End Users

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa